News & Updates

Vaginal estrogen therapy may be safely used to treat genitourinary symptoms in early-stage breast cancer patients with HR-negative tumours and in those concurrently treated with tamoxifen, according to the results of a target trial emulation. However, its use may be detrimental to disease-free survival (DFS) outcomes in patients receiving aromatase inhibitors.

Working out can improve sexual function as well as reduce endocrine sexual symptoms in patients with metastatic breast cancer (mBC), according to data from the PREFERABLE-EFFECT trial.

Consuming cola drinks in high amounts during pregnancy may increase the risk of gestational diabetes mellitus (GDM), while moderate caffeine intake appears to exert a nonsignificant protective effect, as shown in the Kuopio Birth Cohort (KuBiCo).

Topical sildenafil cream appears to deliver promising outcomes for premenopausal women with sexual arousal disorder with or without concomitant decreased sexual desire, with increased arousal and reduced sexual distress, according to the results of an exploratory post hoc efficacy analysis of a phase IIb trial.

Use of metformin monotherapy by fathers during the sperm development period prior to conception does not appear to contribute to an increased risk of major congenital malformations (MCMs) in newborns, reveals a study.

New drug applications approved by US FDA as of 1-15 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Hypertension contributes to a 14-percent increased risk of endometrial cancer, irrespective of diabetes, BMI, and reproductive factors, according to a study.